Knockdown long non-coding RNA HCP5 enhances the radiosensitivity of esophageal carcinoma by modulating AKT signaling activation

Abstract

Recently, long noncoding RNAs (lncRNAs) have been revealed to participate in cancer therapy. Especial in tumor radiotherapy, lncRNAs usually could enhance or restrict the radiosensitivity in different ways. LncRNA HCP5 is highly expressed in esophageal cancer and influenced the malignant behaviors of esophageal cancer cells. However, this study dedicates to clarify if lncRNA HCP5 affects the radiosensitivity of esophageal carcinoma. The expression levels of HCP5 in esophageal cancer and adjacent noncancerous tissue were first analyzed on the TCGA database and then detected by qRT-PCR. The related functional experiments were used to investigate whether the radiosensitivity of esophageal squamous cell carcinoma was affected by the inhibition of HCP5. The expression results showed HCP5 is upregulated in esophageal cancers compared to the normal tissues. Meanwhile, knockdown HCP5 further suppressed the proliferation and promoted the apoptosis of esophageal cancer cells treated with a 2 Gy dose of radiotherapy. Moreover, we uncovered that knockdown HCP5 eliminated radiotherapy resistance by modulating the miR-216a-3p/PDK1 axis to inhibit the AKT activation. Finally, rescue experiments pointed that lowering the miR-216a-3p expression weakened the inhibition effect of knockdown HCP5 on cells treated with radiotherapy. To summary, our results indicate that HCP5 is involved in esophageal carcinoma radiotherapy and knockdown HCP5 enhances the radiosensitivity of esophageal carcinoma by modulating AKT signaling activation.

Hypoxia-Related lncRNA Prognostic Model of Ovarian Cancer Based on Big Data Analysis

“…DNM3OS can also promote tumor progression in gastric cancer [34] and oral cancer [35]. HCP5 has been studied in several kinds of tumors, including ovarian [36], esophageal [37], gastric [38], and colorectal cancer [39]. It has been demonstrated that HCP5 can target miR-525-5p/ PRC1 signaling pathway and can target the Wnt/betacatenin pathway [36].…”

The roles and molecular mechanisms of non-coding RNA in cancer metabolic reprogramming

“…Increasing research has found that the radiotherapy resistance mediated by ncRNAs is associated with the AKT pathway. For instance, increased expression of lncRNA HCP5 has been identified by Guo et al to induce radiotherapy resistance in esophageal cancer tissues by promoting AKT activation through regulating miR-216a-3p/PDK1 axis [ 164 ]. Another well-documented lncRNA DUXAP8 increases radiotherapy resistance in breast cancer cells by activating the PI3K/AKT/mTOR signaling pathway [ 165 ].…”

Roles of long non‑coding RNAs in esophageal cell squamous carcinoma (Review)

“…A study revealed that lncRNA HCP5/miR-216a-3p/PDK1 enhanced radiotherapy resistance in KYSE30 and TE-1 cells by activating the AKT signaling pathway ( 114 ). Similarly, LINC00963/miR-10a/spindle and kinetochore associated complex subunit 1 was found to increase cisplatin resistance in TE-1 and TE-1/DDP cells, thereby promoting CDX growth ( 115 ).…”